Azadeh Mitra, Pan Luying, Qiu Yongchang, Boado Ruben
Shire, 125 Spring Street, Lexington, MA, 02421, USA.
ArmaGen Inc., 26679 Agoura Rd, Calabasas, CA, 92302, USA.
JIMD Rep. 2018;38:89-95. doi: 10.1007/8904_2017_34. Epub 2017 Jun 23.
Clinical studies involving enzyme replacement therapies (ERTs) have increasingly utilized enzymatic activity assays to monitor efficacy and biofunction of the drug; as a result, these assays have become an important part of pharmacokinetic (PK) and pharmacodynamic assessments in ERT trials. This paper presents a two-step enzymatic activity assay for iduronate-2-sulfatase (I2S) (EC 3.1.6.13) which we have optimized to fit in 1 day and to complete in less than 6 h. The rapid assay presented here is a significant improvement over the original two-step method with run time of 24 h which spanned 2 days. The resulting 1 day assay is efficient, robust, reproducible, and better suited for use in pharmacokinetic studies. The method was fully validated in accordance with regulatory agency guidelines so that it could be implemented in PK studies. Validation of the method required additional modifications to circumvent limitations surrounding the calculation of accuracy. This challenge was overcome by developing strategies to determine both the expected and the measured values of validation samples in activity units. Subsequently, the method was validated in accordance with the FDA guidance for the validation of quantitative ligand binding assays (LBAs). Results of method development and optimization with focus on evaluations aimed at reducing the total assay run time as well as a summary of method validation performance are presented in this publication.
涉及酶替代疗法(ERTs)的临床研究越来越多地利用酶活性测定来监测药物的疗效和生物功能;因此,这些测定已成为ERT试验中药代动力学(PK)和药效学评估的重要组成部分。本文介绍了一种用于艾杜糖-2-硫酸酯酶(I2S)(EC 3.1.6.13)的两步酶活性测定方法,我们对其进行了优化,使其能在1天内完成且总时长不到6小时。此处介绍的快速测定方法相较于原始的两步法有显著改进,原始方法运行时间为24小时,跨越2天。由此得到的1天测定方法高效、稳健、可重复,更适合用于药代动力学研究。该方法已按照监管机构指南进行了全面验证,以便能在PK研究中实施。方法验证需要进行额外修改以规避围绕准确度计算的限制。通过制定策略来确定活性单位下验证样品的预期值和测量值,克服了这一挑战。随后,该方法按照美国食品药品监督管理局(FDA)关于定量配体结合测定(LBAs)验证的指南进行了验证。本出版物介绍了方法开发和优化的结果,重点是旨在减少总测定运行时间的评估,以及方法验证性能的总结。